Nclear factor (erythroid-derived 2)-like 2 (NRF2) and its negative regulator, KEAP1 are frequently mutated in cancer, these mutations drive constitutive NRF2 activation and correlate with poor prognosis (Kerins and Ooi, 2018). This evidence concerns the gene NFE2L2 and cancer.